Abstract: This invention is related to the area of characterization of inflammation in relation with the gut microbiota, in metabolic and autoimmune disorders. In particular, it relates to the identification of gene signatures which can be used as a marker predictive of inflammation associated diseases, such as liver-related metabolic disorders, in particular to the evolution of benign steatosis towards its most severe forms (steatohepatitis and cirrhosis) or autoimmune disorders, in particular inflammatory bowel diseases (Crohn's and Ulcerative Colitis). These gene signatures can therefore be used as a means of diagnosis, prognosis, stratification for drug studies, for monitoring patient and for assigning an appropriate treatment.

Abstract: This invention is related to the area of characterization of inflammation in relation with the gut microbiota, in metabolic and autoimmune disorders. In particular, it relates to the identification of gene signatures which can be used as a marker predictive of inflammation associated diseases, such as liver-related metabolic disorders, in particular to the evolution of benign steatosis towards its most severe forms (steatohepatitis and cirrhosis) or autoimmune disorders, in particular inflammatory bowel diseases (Crohn's and Ulcerative Colitis). These gene signatures can therefore be used as a means of diagnosis, prognosis, stratification for drug studies, for monitoring patient and for assigning an appropriate treatment.

Abstract: This invention is related to the area of characterization of inflammation in relation with the gut microbiota, in metabolic and autoimmune disorders. In particular, it relates to the identification of gene signatures which can be used as a marker predictive of inflammation associated diseases, such as liver-related metabolic disorders, in particular to the evolution of benign steatosis towards its most severe forms (steatohepatitis and cirrhosis) or autoimmune disorders, in particular inflammatory bowel diseases (Crohn's and Ulcerative Colitis). These gene signatures can therefore be used as a means of diagnosis, prognosis, stratification for drug studies, for monitoring patient and for assigning an appropriate treatment.

Abstract: This invention is related to the area of characterization of inflammation in relation with the gut microbiota, in metabolic and autoimmune disorders. In particular, it relates to the identification of gene signatures which can be used as a marker predictive of inflammation associated diseases, such as liver-related metabolic disorders, in particular to the evolution of benign steatosis towards its most severe forms (steatohepatitis and cirrhosis) or autoimmune disorders, in particular inflammatory bowel diseases (Crohn's and Ulcerative Colitis). These gene signatures can therefore be used as a means of diagnosis, prognosis, stratification for drug studies, for monitoring patient and for assigning an appropriate treatment.

Abstract: The present invention relates to a method for assessing whether an overweight subject is at risk of gaining weight. The said method comprises the step of detecting at least one gene from a list of bacterial species in a gut DNA sample.

Abstract: The present invention relates to a method for determining whether an overweight subject has a reduced gut bacterial diversity. The said method comprises detecting the presence or absence in a gut DNA sample of at least one gene of at least one bacterial species of Table 1 or Table 2, respectively.

Abstract: The present invention relates to a method for determining whether a subject has a reduced gut bacterial diversity. This method comprises the step of determining the presence or absence in a gut DNA sample of at least one gene from at least one bacterial species from Table 1 or Table 2, respectively.

Abstract: A new method for diagnosing an inflammatory bowel disease is herein described, based on the determination of the absence of at least one gene from the human' gut microbiome.

Abstract: A new method for diagnosing obesity is herein described, based on the determination of the absence of at least one gene from the human' gut microbiome.

Abstract: The nucleic acid coding for an .alpha.-acetolactate synthase from Lactococcus is provided, as well as vectors containing this nucleic acid and the use of these vectors for transforming microorganisms in which the production of .alpha.-acetolactate will be promoted, The nucleic acid comprises one or the other or both of a first segment corresponding to the ilvB gene (which encodes one subunit of .alpha.-acetolactate synthase of Lactococcus lactis subsp. lactis) and a second segment corresponding to the ilvN gene (which encodes a second subunit of .alpha.-acetolactate synthase of Lactococcus lactis subsp. lactis).